LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals
ПЭТ-радиотрейсеры, специфичные к LAT1: разработка и клинический опыт применения нового класса опухолеспецифичных радиофармацевтических препаратов
2025-01-02
SCID: 54.1/9c38jh8v
Discuss with AI
L-type amino acid transporter 1LAT1-specific PET radiotracersamino acid metabolism dysregulationcancer-specific radiopharmaceuticalspositron emission tomography
Figures from the paper
Abstract (AI)
The quest for a cancer-specific positron emission tomography (PET) tracer has been ongoing for decades.Current evidence shows that targeting amino acid metabolism dysregulation is a valid alternative cancer detection method and can complement the conventional approach, which relies on targeting increased glucose metabolism.The rate of amino acid metabolism in all major organs is mostly equally low and does not change in any physiological dynamics.The amino acid metabolism rate only spikes in malignant tissues.PET imaging targeting LAT1 (L-type amino acid transporter 1) demonstrated accurate cancer imaging of various cancer types with nearly negligible background uptake.LAT1 is a pan-cancer biomarker of amino acid metabolism dysregulation.The upregulated LAT1 expression in cancer cells depicts their dynamic behavior and aggressiveness.This review discussed PET radiotracers developed as a LAT1-specific agent and how this new class of cancer-specific radiopharmaceuticals could deliver PET images with clinical properties we yearn for, such as high specificity toward various malignancies, robust non-cancer exclusion (mainly inflammatory reactions), accurate malignant lesion delineation, representative therapeutic monitoring, and long-term prognostication.
Key Findings
1
LAT1 functions as a pan-cancer biomarker of dysregulated amino acid metabolism, with increased expression reflecting cancer-cell aggressiveness and dynamic behavior.
2
LAT1-specific radiotracers may provide high malignancy specificity, exclusion of non-cancerous inflammation, precise lesion delineation, therapeutic monitoring, and long-term prognostic information.
3
LAT1-targeted PET imaging enables accurate visualization of various cancers with nearly negligible uptake in surrounding normal tissues.
4
Targeting amino acid metabolism offers a complementary cancer-imaging strategy to conventional PET imaging of increased glucose metabolism.
5
The reviewed evidence supports development of LAT1-specific PET radiotracers as a new class of cancer-specific radiopharmaceuticals.
Research Object
LAT1-targeted PET radiotracers and their application to imaging malignant tissues across various cancer types
Research Subject
The clinical imaging performance of LAT1-specific radiopharmaceuticals, including cancer specificity, low background uptake, lesion delineation, treatment monitoring, and prognostic value
Publication Details
Publication Date
2025-01-02
Journal
Publisher
ISSN
Cited by
14
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024
The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health2018
ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation2021
Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods2018